Spray drying specialist to invest €19 million in GMP facility expansion
Micro-Sphere expands GMP facility in Switzerland.
Investment is in response to increased market for spray drying and capsule filling for dry powder inhalers.
Spray drying specialist and capsule filling service provider Micro-Sphere is investing 21 million CHF (€19 million) into expanding its GMP manufacturing capabilities at its facility in Switzerland.
The investment, which is in response to increased market for spray drying and capsule filling for dry powder inhalers, will provide the CDMO with greater capacity to handle larger quantities of pharmaceutical powders and commercial volumes of finished dosage forms.
The expanded facility, which will see the GMP production area triple in size, will be home to some of the world’s leading spray drying and capsule filling technologies, which will be operational by Q4 2017.
Micro-Sphere founder and president of the Board, Dr. Michele Müller, said: “Both GMP spray drying as a particle engineering technique and low dose capsule filling are becoming increasingly popular across the market and at present there are very few CDMOs offering this level of capability, especially with our level of niche expertise.
“From our expanded facility, we will continue to produce both clinical and commercial products, with a particular specialism in dry powder inhalers. We look forward to unveiling the technologies we will be adding to our facility in the coming months and what I can promise is it will be some of the finest equipment in the world.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.